Literature DB >> 23593537

Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Jie Li1, Emma Mercer, Xin Gou, Yong-Jie Lu.   

Abstract

Prostate cancer (PCa) is the most commonly diagnosed male malignancy and the second biggest cause of cancer death in men of the Western world. Higher incidences of PCa occur in men from North America, Oceania and Western countries, whereas men from Asia and North Africa have a much lower PCa incidence rate. Investigations into this population disparity of PCa incidence, in order to identify potential preventive factors or targets for the therapeutic intervention of PCa, have found differences in both environmental and genetic variations between these populations. Environmental variations include both diet and lifestyle, which vary widely between populations. Evidence that diet comes into play has been shown by men who immigrate from Eastern to Western countries. PCa incidence in these men is higher than men in their native countries. However the number of immigrants developing PCa still doesn't match native black/white men, therefore genetic factors also contribute to PCa risk, which are supported by familial studies. There are a number of genetic polymorphisms that are differentially presented between Western and Eastern men, which are potentially associated with PCa incidence. Androgen and its receptor (AR) play a major role in PCa development and progression. In this study, we focus on genes involved in androgen biosynthesis and metabolism, as well as those associated with AR pathway, whose polymorphisms affect androgen level and biological or physiological functions of androgen. While many of the genetic polymorphisms in this androgen/AR system showed different frequencies between populations, contradictory evidences exist for most of these genes investigated individually as to the true contribution to PCa risk. More accurate measurements of androgen activity within the prostate are required and further studies need to include more African and Asian subjects. As many of these genetic polymorphisms may contribute to different steps in the same biological/physiological function of androgen and AR pathway, an integrated analysis considering the combined effect of all the genetic polymorphisms may be necessary to assess their contribution to PCa initiation and progression.

Entities:  

Keywords:  Prostate cancer; androgen; androgen receptor; ethnical disparity; genetic polymorphism; risk factors

Year:  2013        PMID: 23593537      PMCID: PMC3623834     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  240 in total

1.  5 alpha-reductase activity and prostate cancer: a case-control study using stored sera.

Authors:  H A Guess; G D Friedman; M C Sadler; F Z Stanczyk; J H Vogelman; J Imperato-McGinley; R A Lobo; N Orentreich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-01       Impact factor: 4.254

2.  Prediagnostic serum hormones and the risk of prostate cancer.

Authors:  A Nomura; L K Heilbrun; G N Stemmermann; H L Judd
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

3.  Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.

Authors:  F Modugno; J L Weissfeld; D L Trump; J M Zmuda; P Shea; J A Cauley; R E Ferrell
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

4.  Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study.

Authors:  R Heikkilä; K Aho; M Heliövaara; M Hakama; J Marniemi; A Reunanen; P Knekt
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

5.  Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men.

Authors:  Tomoko Sonoda; Hiromu Suzuki; Mitsuru Mori; Taiji Tsukamoto; Akira Yokomizo; Seiji Naito; Kiyohide Fujimoto; Yoshihiko Hirao; Naoto Miyanaga; Hideyuki Akaza
Journal:  Eur J Cancer Prev       Date:  2010-03       Impact factor: 2.497

6.  The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men.

Authors:  M Alevizaki; A T Cimponeriu; M Garofallaki; H L Sarika; C C Alevizaki; C Papamichael; G Philippou; E A Anastasiou; J P Lekakis; M Mavrikakis
Journal:  Clin Endocrinol (Oxf)       Date:  2003-12       Impact factor: 3.478

7.  The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study.

Authors:  Ethan M Lange; Aruna V Sarma; Anna Ray; Yunfei Wang; Lindsey A Ho; Sarah A Anderson; Julie M Cunningham; Kathleen A Cooney
Journal:  J Hum Genet       Date:  2008-01-24       Impact factor: 3.172

8.  5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males.

Authors:  R K Ross; L Bernstein; R A Lobo; H Shimizu; F Z Stanczyk; M C Pike; B E Henderson
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

9.  Racial differences in prostate androgen levels in men with clinically localized prostate cancer.

Authors:  James L Mohler; Kris E Gaston; Dominic T Moore; Michael J Schell; Brian L Cohen; Catharina Weaver; Peter Petrusz
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population.

Authors:  R C Sobti; L Gupta; S K Singh; A Seth; P Kaur; H Thakur
Journal:  Cancer Genet Cytogenet       Date:  2008-09
View more
  8 in total

1.  Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice.

Authors:  Seung Joon Kim; Ernest Amankwah; Shahnjayla Connors; Hyun Y Park; Maria Rincon; Heather Cornnell; Ganna Chornokur; Arig Ibrahim Hashim; Junsung Choi; Ya-Yu Tsai; Robert W Engelman; Nagi Kumar; Jong Y Park
Journal:  Cancer Prev Res (Phila)       Date:  2014-02-05

Review 2.  Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective.

Authors:  Jeremy Yuen Chun Teoh; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2016-06-02       Impact factor: 2.370

3.  Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer.

Authors:  Xueying Mao; Jie Li; Xingxing Xu; Lara K Boyd; Weiyang He; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Guangwen Cao; Daniel Berney; Guosheng Ren; Xin Gou; Hongwei Zhang; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

4.  Prostate cancer health disparities: An immuno-biological perspective.

Authors:  Sanjay Kumar; Rajesh Singh; Shalie Malik; Upender Manne; Manoj Mishra
Journal:  Cancer Lett       Date:  2017-11-15       Impact factor: 8.679

Review 5.  Racial disparities in prostate cancer: a molecular perspective.

Authors:  Arun Bhardwaj; Sanjeev K Srivastava; Mohammad Aslam Khan; Vijay K Prajapati; Seema Singh; James E Carter; Ajay P Singh
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01

Review 6.  Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis.

Authors:  Zhiqiang Qin; Xiao Li; Peng Han; Yuxiao Zheng; Hanyu Liu; Jingyuan Tang; Chengdi Yang; Jianzhong Zhang; Kunpeng Wang; Xiaokang Qi; Min Tang; Wei Wang; Wei Zhang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

7.  Prostate cancer in the Arab population. An overview.

Authors:  Osman Z Al-Abdin; Ibrahim Z Al-Beeshi
Journal:  Saudi Med J       Date:  2018-05       Impact factor: 1.484

Review 8.  Mast cells as a potential prognostic marker in prostate cancer.

Authors:  Gianluigi Taverna; Guido Giusti; Mauro Seveso; Rodolfo Hurle; Piergiuseppe Colombo; Sanja Stifter; Fabio Grizzi
Journal:  Dis Markers       Date:  2013-11-11       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.